AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.51 |
Market Cap | 21.02M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -7.22 |
PE Ratio (ttm) | -0.43 |
Forward PE | n/a |
Analyst | Buy |
Ask | 3.4 |
Volume | 40,125 |
Avg. Volume (20D) | 25,370 |
Open | 3.10 |
Previous Close | 3.00 |
Day's Range | 3.00 - 3.13 |
52-Week Range | 2.37 - 7.00 |
Beta | undefined |
About PYPD
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is head...
Analyst Forecast
According to 2 analyst ratings, the average rating for PYPD stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 239.81% from the latest price.